Annual CFF
$25.58 M
+$20.71 M+424.85%
December 31, 2023
Summary
- As of February 7, 2025, CAPR annual cash flow from financing activities is $25.58 million, with the most recent change of +$20.71 million (+424.85%) on December 31, 2023.
- During the last 3 years, CAPR annual CFF has fallen by -$7.80 million (-23.37%).
- CAPR annual CFF is now -23.37% below its all-time high of $33.38 million, reached on December 31, 2020.
Performance
CAPR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$67.33 M
+$65.26 M+3157.07%
September 30, 2024
Summary
- As of February 7, 2025, CAPR quarterly cash flow from financing activities is $67.33 million, with the most recent change of +$65.26 million (+3157.07%) on September 30, 2024.
- Over the past year, CAPR quarterly CFF has increased by +$65.26 million (+3157.07%).
- CAPR quarterly CFF is now at all-time high.
Performance
CAPR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$94.85 M
+$67.11 M+241.86%
September 30, 2024
Summary
- As of February 7, 2025, CAPR TTM cash flow from financing activities is $94.85 million, with the most recent change of +$67.11 million (+241.86%) on September 30, 2024.
- Over the past year, CAPR TTM CFF has increased by +$67.11 million (+241.86%).
- CAPR TTM CFF is now at all-time high.
Performance
CAPR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
CAPR Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +424.9% | +3157.1% | +241.9% |
| 3 y3 years | -23.4% | +2182.7% | +1846.1% |
| 5 y5 years | +273.2% | +2182.7% | +1846.1% |
CAPR Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +424.9% | at high | >+9999.0% | at high | +4722.9% |
| 5 y | 5-year | -23.4% | +424.9% | at high | >+9999.0% | at high | +4722.9% |
| alltime | all time | -23.4% | -100.0% | at high | >+9999.0% | at high | -100.0% |
Capricor Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $67.33 M(+3157.1%) | $94.85 M(+241.9%) |
| Jun 2024 | - | $2.07 M(-9.7%) | $27.75 M(-0.4%) |
| Mar 2024 | - | $2.29 M(-90.1%) | $27.87 M(+8.9%) |
| Dec 2023 | $25.58 M(+424.8%) | $23.17 M(>+9900.0%) | $25.58 M(+377.0%) |
| Sep 2023 | - | $221.10 K(-89.9%) | $5.36 M(-23.6%) |
| Jun 2023 | - | $2.19 M(>+9900.0%) | $7.02 M(+44.8%) |
| Mar 2023 | - | $3900.00(-99.9%) | $4.85 M(-0.5%) |
| Dec 2022 | $4.87 M(-75.9%) | $2.95 M(+56.7%) | $4.87 M(+147.8%) |
| Sep 2022 | - | $1.88 M(>+9900.0%) | $1.97 M(-70.4%) |
| Jun 2022 | - | $15.00 K(-45.5%) | $6.65 M(-13.3%) |
| Mar 2022 | - | $27.50 K(-35.1%) | $7.67 M(-62.1%) |
| Dec 2021 | $20.23 M(-39.4%) | $42.40 K(-99.4%) | $20.23 M(-6.7%) |
| Sep 2021 | - | $6.57 M(+534.3%) | $21.68 M(+25.4%) |
| Jun 2021 | - | $1.04 M(-91.8%) | $17.29 M(-58.3%) |
| Mar 2021 | - | $12.58 M(+740.9%) | $41.41 M(+24.1%) |
| Dec 2020 | $33.38 M(+263.7%) | $1.50 M(-31.3%) | $33.38 M(-8.5%) |
| Sep 2020 | - | $2.18 M(-91.3%) | $36.50 M(-1.1%) |
| Jun 2020 | - | $25.16 M(+453.0%) | $36.91 M(+200.2%) |
| Mar 2020 | - | $4.55 M(-1.3%) | $12.29 M(+34.0%) |
| Dec 2019 | $9.18 M(+33.9%) | $4.61 M(+78.2%) | $9.18 M(+80.7%) |
| Sep 2019 | - | $2.59 M(+374.3%) | $5.08 M(+43.3%) |
| Jun 2019 | - | $545.70 K(-61.9%) | $3.54 M(-38.6%) |
| Mar 2019 | - | $1.43 M(+179.9%) | $5.77 M(-15.7%) |
| Dec 2018 | $6.85 M(-40.8%) | $512.00 K(-51.4%) | $6.85 M(-26.8%) |
| Sep 2018 | - | $1.05 M(-62.0%) | $9.37 M(-27.6%) |
| Jun 2018 | - | $2.78 M(+10.5%) | $12.94 M(-8.2%) |
| Mar 2018 | - | $2.51 M(-17.0%) | $14.09 M(+21.7%) |
| Dec 2017 | $11.58 M(-37.8%) | $3.03 M(-34.5%) | $11.58 M(+35.4%) |
| Sep 2017 | - | $4.62 M(+17.5%) | $8.55 M(-45.3%) |
| Jun 2017 | - | $3.93 M(>+9900.0%) | $15.63 M(+14.1%) |
| Mar 2017 | - | $0.00(0.0%) | $13.70 M(-26.5%) |
| Dec 2016 | $18.63 M(+13.0%) | $0.00(-100.0%) | $18.63 M(0.0%) |
| Sep 2016 | - | $11.70 M(+484.9%) | $18.63 M(+168.4%) |
| Jun 2016 | - | $2.00 M(-59.4%) | $6.94 M(+40.5%) |
| Mar 2016 | - | $4.93 M(>+9900.0%) | $4.94 M(-70.0%) |
| Dec 2015 | $16.49 M(+216.8%) | $0.00(-100.0%) | $16.49 M(-0.0%) |
| Sep 2015 | - | $10.10 K(+2425.0%) | $16.49 M(-3.0%) |
| Jun 2015 | - | $400.00(-100.0%) | $17.00 M(-21.6%) |
| Mar 2015 | - | $16.48 M(>+9900.0%) | $21.69 M(+316.6%) |
| Dec 2014 | $5.21 M(+32.6%) | $200.00(-100.0%) | $5.21 M(+0.0%) |
| Sep 2014 | - | $516.30 K(-89.0%) | $5.20 M(-32.9%) |
| Jun 2014 | - | $4.69 M(>+9900.0%) | $7.76 M(+152.7%) |
| Mar 2014 | - | $900.00(-150.0%) | $3.07 M(-21.8%) |
| Dec 2013 | $3.93 M(-21.5%) | -$1800.00(-100.1%) | $3.93 M(-49.2%) |
| Sep 2013 | - | $3.07 M(>+9900.0%) | $7.73 M(+65.8%) |
| Jun 2013 | - | $1800.00(-99.8%) | $4.66 M(-20.4%) |
| Mar 2013 | - | $857.30 K(-77.5%) | $5.86 M(+17.1%) |
| Dec 2012 | $5.00 M | $3.81 M(>+9900.0%) | $5.00 M(+317.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | $0.00(-100.0%) | $1.20 M(0.0%) |
| Jun 2012 | - | $1.19 M(>+9900.0%) | $1.20 M(-48.1%) |
| Mar 2012 | - | $0.00(-100.0%) | $2.31 M(-0.3%) |
| Dec 2011 | $2.31 M(-48.9%) | $2500.00(>+9900.0%) | $2.31 M(+0.1%) |
| Sep 2011 | - | $0.00(-100.0%) | $2.31 M(-0.3%) |
| Jun 2011 | - | $2.30 M(>+9900.0%) | $2.32 M(-48.9%) |
| Mar 2011 | - | $6200.00(>+9900.0%) | $4.53 M(+0.1%) |
| Dec 2010 | $4.52 M(+29.1%) | $0.00(-100.0%) | $4.52 M(-1.6%) |
| Sep 2010 | - | $6200.00(-99.9%) | $4.60 M(-42.7%) |
| Jun 2010 | - | $4.52 M(>+9900.0%) | $8.02 M(+128.9%) |
| Mar 2010 | - | $0.00(-100.0%) | $3.50 M(0.0%) |
| Dec 2009 | $3.50 M(>+9900.0%) | $73.90 K(-97.8%) | $3.50 M(+2.2%) |
| Sep 2009 | - | $3.43 M(>+9900.0%) | $3.43 M(>+9900.0%) |
| Jun 2009 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2008 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2008 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Jun 2008 | - | $0.00(0.0%) | $19.87 M(0.0%) |
| Mar 2008 | - | $0.00(0.0%) | $19.87 M(0.0%) |
| Dec 2007 | $19.87 M(+396.8%) | $0.00(-100.0%) | $19.87 M(-16.6%) |
| Sep 2007 | - | $19.87 M(>+9900.0%) | $23.82 M(+496.6%) |
| Jun 2007 | - | $0.00(0.0%) | $3.99 M(-0.1%) |
| Mar 2007 | - | $0.00(-100.0%) | $3.99 M(-0.1%) |
| Dec 2006 | $4.00 M(>+9900.0%) | $3.94 M(+8204.8%) | $4.00 M(+7107.2%) |
| Sep 2006 | - | $47.50 K(+1879.2%) | $55.50 K(+288.1%) |
| Jun 2006 | - | $2400.00(-54.7%) | $14.30 K(+17.2%) |
| Mar 2006 | - | $5300.00(+1666.7%) | $12.20 K(-29.9%) |
| Dec 2005 | $17.40 K(+16.0%) | $300.00(-95.2%) | $17.40 K(-18.7%) |
| Sep 2005 | - | $6300.00(+2000.0%) | $21.40 K(+35.4%) |
| Jun 2005 | - | $300.00(-97.1%) | $15.80 K(+1.9%) |
| Mar 2005 | - | $10.50 K(+144.2%) | $15.50 K(+3.3%) |
| Dec 2004 | $15.00 K(-31.5%) | $4300.00(+514.3%) | $15.00 K(-1.3%) |
| Sep 2004 | - | $700.00(>+9900.0%) | $15.20 K(-11.1%) |
| Jun 2004 | - | $0.00(-100.0%) | $17.10 K(-38.7%) |
| Mar 2004 | - | $10.00 K(+122.2%) | $27.90 K(+26.8%) |
| Dec 2003 | $21.90 K(+54.2%) | $4500.00(+73.1%) | $22.00 K(+13.4%) |
| Sep 2003 | - | $2600.00(-75.9%) | $19.40 K(-27.9%) |
| Jun 2003 | - | $10.80 K(+163.4%) | $26.90 K(+47.0%) |
| Mar 2003 | - | $4100.00(+115.8%) | $18.30 K(+28.9%) |
| Dec 2002 | $14.20 K(>+9900.0%) | $1900.00(-81.2%) | $14.20 K(+15.4%) |
| Sep 2002 | - | $10.10 K(+359.1%) | $12.30 K(+459.1%) |
| Jun 2002 | - | $2200.00(>+9900.0%) | $2200.00(>+9900.0%) |
| Mar 2002 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2001 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2001 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2001 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2001 | - | $0.00 | $0.00 |
| Dec 2000 | $50.50 K(>+9900.0%) | - | - |
| Dec 1999 | $0.00 | - | - |
FAQ
- What is Capricor Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Capricor Therapeutics?
- What is Capricor Therapeutics annual CFF year-on-year change?
- What is Capricor Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Capricor Therapeutics?
- What is Capricor Therapeutics quarterly CFF year-on-year change?
- What is Capricor Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Capricor Therapeutics?
- What is Capricor Therapeutics TTM CFF year-on-year change?
What is Capricor Therapeutics annual cash flow from financing activities?
The current annual CFF of CAPR is $25.58 M
What is the all time high annual CFF for Capricor Therapeutics?
Capricor Therapeutics all-time high annual cash flow from financing activities is $33.38 M
What is Capricor Therapeutics annual CFF year-on-year change?
Over the past year, CAPR annual cash flow from financing activities has changed by +$20.71 M (+424.85%)
What is Capricor Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of CAPR is $67.33 M
What is the all time high quarterly CFF for Capricor Therapeutics?
Capricor Therapeutics all-time high quarterly cash flow from financing activities is $67.33 M
What is Capricor Therapeutics quarterly CFF year-on-year change?
Over the past year, CAPR quarterly cash flow from financing activities has changed by +$65.26 M (+3157.07%)
What is Capricor Therapeutics TTM cash flow from financing activities?
The current TTM CFF of CAPR is $94.85 M
What is the all time high TTM CFF for Capricor Therapeutics?
Capricor Therapeutics all-time high TTM cash flow from financing activities is $94.85 M
What is Capricor Therapeutics TTM CFF year-on-year change?
Over the past year, CAPR TTM cash flow from financing activities has changed by +$67.11 M (+241.86%)